Reuters: Health
Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.
Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
Reuters: Health
Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.
Reuters: Health
Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment